Kang R X
Department of Ophthalmology, Shandong Provincial Hospital, Jinan.
Zhonghua Yan Ke Za Zhi. 1993 Nov;29(6):336-9.
The IOP depressive effect of puerarin, a beta-receptor blocker, was found to be optimal at the concentration of 1% in animal experiments. Clinical trial use on glaucoma patients (80 cases, 143 eyes) demonstrated good IOP depressive effect on primary open--or closed-angle glaucoma and secondary glaucoma. For all types of glaucoma not satisfactorily controlled by conventional drugs such as timolol and pilocarpine or by operation, the addition of puerarin also yielded favorably results. The total effective rate was 70.63%. The raw herb is produced in quantity, hence puerarin is a promising agent for the treatment of glaucoma in China.
在动物实验中发现，β受体阻滞剂葛根素的眼压降低作用在浓度为1%时最为理想。对青光眼患者（80例，143只眼）进行的临床试验表明，其对原发性开角型或闭角型青光眼以及继发性青光眼具有良好的眼压降低作用。对于所有类型的青光眼，若常规药物如噻吗洛尔和毛果芸香碱治疗效果不佳或手术治疗效果不理想，加用葛根素也能取得良好效果。总有效率为70.63%。该生药产量大，因此葛根素在中国是一种有前景的青光眼治疗药物。
